Accretion Pharmaceuticals Key Ratios
NSE: ACCPL
₹207.00
₹7.45
(3.73%)
As on 31-Aug-2026IST
Market cap
₹230 Cr
Revenue (TTM)
₹90 Cr
P/E Ratio
23.8
P/B Ratio
4.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 56.21 | -- | -- |
| EBIT | -- | -- | 23.91 | -- | -- |
| Net Profit | -- | -- | 42.31 | -- | -- |
| EPS | -- | -- | 4.59 | -- | -- |
| Book Value | -- | -- | 152.37 | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| -- | -- | 15.36 | 19.36 | 17.52 |
| Net Margin
| -- | -- | 10.76 | 11.82 | 11.13 |
| Return on equity
| -- | -- | 28.72 | 65.71 | 27.18 |
| Return on Capital
| -- | -- | 29.77 | 46.42 | 12.62 |
| Return on Assets
| -- | -- | 16.59 | 20.18 | 5.44 |
| Debt to Equity (x)
| -- | -- | 0.24 | 0.93 | 2.45 |
Profitability
ROCE
29.77
Higher than Peers by 14.02
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
29.77
|
46.42
|
12.62
|
--
|
--
|
|
Peer Median
|
15.74
|
14.72
|
18.85
|
11.60
|
--
|
ROE
28.72
Higher than Peers by 14.97
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
28.72
|
65.71
|
27.18
|
--
|
--
|
|
Peer Median
|
13.75
|
11.67
|
14.92
|
11.46
|
--
|
ROA
16.59
Higher than Peers by 8.42
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
16.59
|
20.18
|
5.44
|
--
|
--
|
|
Peer Median
|
8.17
|
7.86
|
9.06
|
6.44
|
--
|
EBIT Margin
15.36
Higher than Peers by 0.57
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
15.36
|
19.36
|
17.52
|
--
|
--
|
|
Peer Median
|
14.78
|
15.03
|
14.71
|
12.37
|
--
|
Net Margin
10.76
Higher than Peers by 2.22
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
10.76
|
11.82
|
11.13
|
--
|
--
|
|
Peer Median
|
8.54
|
9.33
|
8.49
|
10.02
|
--
|
Cash Profit Margin
12.14
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
12.14
|
13.19
|
12.85
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
56.21
Higher than Peers by 42.09
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
56.21
|
329.70
|
--
|
--
|
--
|
|
Peer Median
|
14.12
|
10.27
|
11.85
|
9.08
|
--
|
EBIT Growth
23.91
Higher than Peers by 2.32
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
23.91
|
374.78
|
--
|
--
|
--
|
|
Peer Median
|
21.59
|
24.15
|
28.00
|
-3.12
|
--
|
Net Profit Growth
42.31
Higher than Peers by 13.99
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
42.31
|
355.08
|
--
|
--
|
--
|
|
Peer Median
|
28.31
|
30.29
|
36.51
|
-0.85
|
--
|
EPS Growth
4.59
Lower than Peers by 9.66
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
4.59
|
323.34
|
--
|
--
|
--
|
|
Peer Median
|
14.25
|
24.50
|
--
|
-6.82
|
--
|
Book Value Growth
243.37
--
Year on year growth in book value per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
243.37
|
176.46
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.24
Higher than Peers by 0.04
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
0.24
|
0.93
|
2.45
|
--
|
--
|
|
Peer Median
|
0.20
|
0.23
|
0.20
|
0.15
|
--
|
Short term debt to equity ratio
0.16
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
0.16
|
0.61
|
0.76
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.90
Higher than Peers by 1.07
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
2.90
|
1.44
|
1.47
|
--
|
--
|
|
Peer Median
|
1.83
|
1.79
|
1.96
|
2.08
|
--
|
Quick Ratio
1.54
Higher than Peers by 0.30
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
1.54
|
0.55
|
0.50
|
--
|
--
|
|
Peer Median
|
1.23
|
1.47
|
1.44
|
1.58
|
--
|
Interest Coverage
16.03
Higher than Peers by 7.62
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
16.03
|
7.79
|
6.00
|
--
|
--
|
|
Peer Median
|
8.41
|
9.42
|
8.58
|
15.41
|
--
|
Operating Efficiency
Debtors to sales
24.99
Lower than Peers by 0.30
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
24.99
|
20.32
|
43.47
|
--
|
--
|
|
Peer Median
|
25.29
|
25.82
|
26.12
|
22.96
|
--
|
Asset Turnover
1.54
Higher than Peers by 0.80
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
1.54
|
1.70
|
0.49
|
--
|
--
|
|
Peer Median
|
0.73
|
0.75
|
0.77
|
0.65
|
--
|
Receivable days
69.36
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
69.36
|
55.55
|
158.67
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
99.74
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
99.74
|
111.60
|
395.71
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
37.40
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
37.40
|
64.77
|
256.34
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
131.70
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
131.70
|
102.38
|
298.04
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
7.31
Lower than Peers by 32.59
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
7.31
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.90
|
39.70
|
33.48
|
37.74
|
--
|
Price / Book Value
1.35
Lower than Peers by 2.91
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
1.35
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.26
|
3.72
|
4.21
|
3.22
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
0.16
|
0.21
|
0.57
|
--
|
EV/EBITDA
5.21
Lower than Peers by 23.51
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
5.21
|
1.86
|
6.64
|
--
|
--
|
|
Peer Median
|
28.71
|
30.23
|
29.90
|
28.81
|
--
|
Market Cap
71
Lower than Peers by 5,966
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Accretion Pharmaceuticals
|
71
|
--
|
--
|
--
|
--
|
|
Peer Median
|
6,036
|
4,851
|
2,099
|
15,272
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
